UNSPSC 51294302: Losindole

This classification denotes an antidepressant agent with the molecular formula C19H20ClN, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IX8TM6153H, chemically known as (- )-(3a alpha,4alpha,9a alpha)-6-chloro-3a,4,9,9a-tetrahydro-2-methyl-4-phenylbenz(f)isoindoline. but generally known as losindole, which bears US NIH Compound Identifier 3045392. European Medicines Agency schedules Losindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08595MIG.

UNSPSC 51294302 Losindole is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone and drug deactivation systems for community health and opioid-response programs, as well as generic multi-source pharmaceuticals and over-the-counter products for distribution through government health facilities and cooperative purchasing networks. Recent solicitations show activity driven by county health departments, state pharmacy benefit programs, and multistate cooperative purchasing alliances seeking to establish supply contracts for emergency response medications and routine pharmaceutical inventories. The scope spans both specialized public-health interventions—such as Seminole County's annual procurement of naloxone and drug deactivation systems—and broader pharmaceutical supply agreements serving multiple jurisdictions through authorized wholesaler networks.

Activity under the code clusters in Florida and Minnesota, with interstate reach through multistate cooperative purchasing mechanisms. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (noting a discrepancy in posted versus deadline dates in the source). The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, representing exploratory procurement activity preceding formal solicitation. All three opportunities require vendor compliance with federal pharmaceutical regulations, including Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and demand electronic submission through state procurement portals.